And that I totally understand, you are definitely not alone.
evidently, you don’t know the market in Europe … because the risk I spoke of is not one of inability but one of unsalability (or at least very very difficult) for the product
You are correct, I don’t really know the market in Europe. But one of the most interesting things about all this is as ladyj said - this clone, Gemini, IS in Europe and many of his foals ARE in Europe. Several are in France. Gemini is approved AES and Z. He was available in Belgium 5 years ago. A stallion son, presented to BWP, sold for 33,000 euros.
From one site:
"His first foals are born in Belgium in 2013. Several were selected and sold well on sales of foals, including Gem Carnute Z when Z sales Lanaken.
Joris de Brabander , best breeder in Europe, 40 mares inseminated Gemini alone.
In 2014, He covered in France, but also about 60 mares in Belgium and has been used in the Netherlands, Spain, Hungary and the USA.
"
So clearly there are some who don’t care about the clone aspect, and look instead at what his DNA (which is again 100% identical to the original) brings to the gene pool.
They are the early adopters, and that’s not something that is for everyone, but it’s a set of people that is dearly needed when it comes to getting new products to market
Sure they are! There have been quite a few threads here alone, probably 1-2 a year, on “who are heavy or full TB sires for eventing”